August 09, 2007
Dr. Catherine T. Hunt, 2007 President, American Chemical Society, 8-9-07
Dr. Catherine T. (Katie) Hunt is the 2007 President of the American Chemical Society, the world's largest scientific society. She is also an employee of Rohm and Haas in Spring House, PA. She is Leader of Technology Partnerships (Emerging Technologies) for Rohm and Haas and her background is in catalysis and inorganic chemistry. In her 23 years in industry, Dr. Hunt has applied her background in these two areas across a broad range of electronics, materials, catalysis, hydrogen, coatings and health care.
Dr. Hunt received an A.B. degree in chemistry (cum laude with honors) in 1977 from Smith College in Massachusetts and a Ph.D. in chemistry from the University of California, Davis, in 1981. An ACS member since 1977, Dr. Hunt has been involved in numerous Society activities, including membership in the Philadelphia Local Section and the Divisions of Analytical Chemistry, Industrial and Engineering Chemistry and Inorganic Chemistry.
The American Chemical Society is a nonprofit organization, chartered by the U.S. Congress, with a multidisciplinary membership of more than 160,000 chemists and chemical engineers. ACS publishes numerous scientific journals and databases, convenes major research conferences and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, OH.
ACS is a strong and successful advocate for the chemical sciences from education to legislation; an important hub of technical activities from meetings to publications and from divisions to websites; and a growing pool of resources from networks to workshops.
Dr. Eric Isaacs, Director, Center for Nanoscale Materials at Argonne National Laboratory, and Professor of Physics, James Franck Institute, University of Chicago, 8-9-07
Dr. Eric D. Isaacs is the Director of the Center for Nanoscale Materials at Argonne National Laboratory and Professor of Physics in the James Franck Institute at the University of Chicago. He received his Ph.D. from Massachusetts Institute of Technology in 1988 in the area of magnetic semiconductors and was a post-doc at Bell Laboratories (1988-1990) studying magnetism and superconductivity, mostly with synchrotron-based x-ray techniques. During his 13-year tenure at Bell Laboratories he was a Member of Technical Staff (1990-2000), Director of the Materials Physics Research Department (2000-2001), and Director of the Semiconductor Physics Department (2001-2003).
Dr. Isaacs has served on numerous national review and advisory committees including the APS Division of Materials Physics (2002-2005) and the DOE Basic Energy Sciences Advisory Committee (2002 - present). He is a fellow of the American Physical Society (2001).
Dr. Isaacs’s current research centers on studies of novel electronic and magnetic materials with a particular focus on creating images of new phenomena in reciprocal and real space at the nanoscale. Recent accomplishments include the direct observation of the cross-over to quantum dominated spin dynamics near a quantum critical point in the model magnetic system chromium. In order to achieve many of his results he has been a developer of modern synchrotron-based x-ray scattering techniques including inelastic x-ray scattering, x-ray photon correlation spectroscopy, and hard x-ray nano-probe.
The Center for Nanoscale Materials at Argonne National Laboratory is a national resource for the United States to foster new research capabilities in nanoscale synthesis and processing, and plays a key role in the U.S. Department of Energy’s participation in the interagency National Nanotechnology Initiative. The center’s mission includes supporting basic research and advanced instrumentation development for the creation of novel materials, using both top-down and bottom-up self-assembly, that provide new insights at the nanoscale level. The facility also supports a user program through peer-reviewed proposals that is open to academic, industrial, government, and international potential users.
Areas of expertise include Electronic and magnetic materials and devices
Dr. Charis Eng, Chair and Founding Director, Genomic Medicine Institute, Cleveland Clinic Foundation, and Professor and Vice Chairman, Department of Genetics, Case Western Reserve University School of Medicine, 8-9-07
Dr. Charis Eng is the Chair and founding Director of the Genomic Medicine Institute of the Cleveland Clinic Foundation, founding Director and attending clinical cancer geneticist of the institute’s clinical component, the Center for Personalized Genetic Healthcare, and Professor and Vice Chairman of the Department of Genetics at Case Western Reserve University School of Medicine.
Dr. Eng holds a joint appointment as Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine and is a full member of Cleveland Clinic’s Taussig Cancer Center and a member of the CASE Comprehensive Cancer Center. She was recently honored by the designation National Scholar of the Davis Heart and Lung Research Institute of The Ohio State University, and continues to hold an honorary appointment at the University of Cambridge.
Dr. Eng’s research interests may be broadly characterized as clinical cancer genetics translational research. Her work on RET testing in multiple endocrine neoplasia type 2 and the characterization of the widening clinical spectra of PTEN gene mutations have been acknowledged as the paradigm for the practice of clinical cancer genetics.
Dr. Eng has published over 230 peer-reviewed original papers in such journals as the New England Journal of Medicine, JAMA, Lancet, Nature Genetics, Nature. She has received numerous awards and honors including election to the American Society of Clinical Investigation, to the Association of American Physicians and as Fellow of AAAS, the Doris Duke Distinguished Clinical Scientist Award and named a Local Legend from Ohio bestowed by the American Medical Women’s Association in conjunction with the U.S. Senate on women physicians who have demonstrated commitment, originality, innovation and/or creativity in their fields of medicine.
Dr. Eng has been elected to a three-year term on the Board of Directors of the American Society of Human Genetics and will serve a four-year term on the Board of Scientific Directors of the National Human Genome Research Institute beginning in Autumn, 2007.